Remove 2020 Remove Individual Remove Provider Remove Utilities
article thumbnail

Differences in primary care utilization by primary care availability in the first year of Virginia Medicaid Expansion [Health care disparities]

Annals of Family Medicine

Importantly, Virginia's Medicaid expansion reduced cost-related barriers to accessing care for over 700,000 individuals. Setting or Dataset: 2019-2020 Virginia Department of Medical Assistance Services database (demographic, enrollment, and claims data). Of these, 117,481 (57.2%) individuals had at least one primary care visit.

article thumbnail

Episode 148: Antiracism in Medicine Series Episode 4 – Dismantling Race-Based Medicine Part 2: Clinical Perspectives

The Clinical Problem Solvers

Moreover, center patients not only in discussions about individual decision-making but in constructing and drawing meaning from the research. Our esteemed publications should ensure that investigations that utilize racial variables follow these guidelines before being published. September 8, 2020. Published July 2, 2020.

Clinic 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Could the Road to an AKS Violation Be Paved with Good Intentions? Pfizer Asks SCOTUS

FDA Law Blog

The Court found that there is at best little utility in interpreting the AKS by reference to the BIS. As Pfizer has argued throughout this legal battle, its proposed copay assistance program “poses no risk of corrupting independent decision making” or of inducing improper utilization of tafamidis. Pfizer’s Petition to SCOTUS.

article thumbnail

3 in 1 Guidance Issued by FDA Covering Formal Dispute Resolution, Administrative Hearings and Consolidated Proceedings for OTC Monograph Drugs

FDA Law Blog

The CARES Act also provides for an administrative hearing process that may be utilized under certain conditions following the formal dispute resolution process. FDA will determine the total number of individuals who can attend the consolidated proceedings in person. This is the third topic included in the new draft guidance.

article thumbnail

Episode 275: Anti-Racism in Medicine Series – Episode 19 – Reframing the Opioid Epidemic: Anti-Racist Praxis, Racial Health Inequities, and Harm Reduction

The Clinical Problem Solvers

Pearls: In 2020, American Indian and Alaska Native (Indigenous) communities experienced the highest drug overdose mortality rate of any racial or ethnic group, also surpassing rates among the non-Hispanic white population. They can use their training and privilege to advocate for meaningful policy reform.

article thumbnail

RCT of Palliative Care for Heart Failure and Lung Disease: David Bekelman and Lyndsay DeGroot

GeriPal

Summary Transcript Summary In a JAMA 2020 systematic review of palliative care for non-cancer serious illness, Kieran Quinn found many positives, as we discussed on our podcast and in our editorial. With their regular providers? However, its main predictors are age, comorbidity, and healthcare utilization. In their communities?

article thumbnail

Better Late Than Never – Unpacking FDA’s Highly Anticipated (and Long Overdue) Draft Guidance on Diversity Action Plans

FDA Law Blog

Where sponsors plan to conduct several clinical studies that may be subject to DAP requirements, the plan for each study should reflect a strategy that leads to an overall proportionate representation, even though individual studies may not. providing language assistance); Reducing participant burden (e.g.,

Clinic 59